Safe and appropriate use of diclofenac in chronic kidney disease: An Indian perspective
Pain is most common symptom associated with progressive disorder, chronic kidney disease (CKD), and is usually undertreated during the early stages of CKD. So, present review was conducted to evaluate the challenges for the management of pain in CKD patients and addresses the scope for considering D...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
| Series: | Journal of Family Medicine and Primary Care |
| Subjects: | |
| Online Access: | http://www.jfmpc.com/article.asp?issn=2249-4863;year=2021;volume=10;issue=7;spage=2450;epage=2456;aulast=Sheth |
| _version_ | 1818647118037909504 |
|---|---|
| author | Sharad Sheth Sneha Thakur Anup Thorat Pankaj Gupta |
| author_facet | Sharad Sheth Sneha Thakur Anup Thorat Pankaj Gupta |
| author_sort | Sharad Sheth |
| collection | DOAJ |
| description | Pain is most common symptom associated with progressive disorder, chronic kidney disease (CKD), and is usually undertreated during the early stages of CKD. So, present review was conducted to evaluate the challenges for the management of pain in CKD patients and addresses the scope for considering Diclofenac as suitable alternative for pain management in CKD patient. The database PubMed and Google Scholar were searched from 1970 to Dec 2020 for literature published in English and all studies, review articles that examined the use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in pain management in CKD patients were included. Literatures revealed that there is a considerable challenge in appropriate management of pain in CKD patients include understanding the altered pharmacokinetics and pharmacodynamics of analgesics in CKD patients and the risk of acute interstitial nephritis. The shorter duration of analgesics is acceptable and considered to pose a low risk of acute interstitial nephritis in patients. Considering that Diclofenac has a shorter half-life and high efficacy, it may be well tolerated in patients with CKD. The acceptance of Diclofenac is partly attributed to being a potent COX-2 inhibitor with the lowest IC50 and its rapid onset of action at lowest effective dose. In conclusion, diclofenac may be well tolerated in patients of renal impairment when used at lowest effective dose for shortest dose duration. Diclofenac is worthy of consideration in mild to moderate cases of CKD. For effective pain management, it is vital to evaluate the tolerability and efficacy of the available analgesics critically. |
| first_indexed | 2024-12-17T00:57:27Z |
| format | Article |
| id | doaj.art-d7a8fd1f495c415e85b7ead41f29cd47 |
| institution | Directory Open Access Journal |
| issn | 2249-4863 |
| language | English |
| last_indexed | 2024-12-17T00:57:27Z |
| publishDate | 2021-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Family Medicine and Primary Care |
| spelling | doaj.art-d7a8fd1f495c415e85b7ead41f29cd472022-12-21T22:09:34ZengWolters Kluwer Medknow PublicationsJournal of Family Medicine and Primary Care2249-48632021-01-011072450245610.4103/jfmpc.jfmpc_2358_20Safe and appropriate use of diclofenac in chronic kidney disease: An Indian perspectiveSharad ShethSneha ThakurAnup ThoratPankaj GuptaPain is most common symptom associated with progressive disorder, chronic kidney disease (CKD), and is usually undertreated during the early stages of CKD. So, present review was conducted to evaluate the challenges for the management of pain in CKD patients and addresses the scope for considering Diclofenac as suitable alternative for pain management in CKD patient. The database PubMed and Google Scholar were searched from 1970 to Dec 2020 for literature published in English and all studies, review articles that examined the use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in pain management in CKD patients were included. Literatures revealed that there is a considerable challenge in appropriate management of pain in CKD patients include understanding the altered pharmacokinetics and pharmacodynamics of analgesics in CKD patients and the risk of acute interstitial nephritis. The shorter duration of analgesics is acceptable and considered to pose a low risk of acute interstitial nephritis in patients. Considering that Diclofenac has a shorter half-life and high efficacy, it may be well tolerated in patients with CKD. The acceptance of Diclofenac is partly attributed to being a potent COX-2 inhibitor with the lowest IC50 and its rapid onset of action at lowest effective dose. In conclusion, diclofenac may be well tolerated in patients of renal impairment when used at lowest effective dose for shortest dose duration. Diclofenac is worthy of consideration in mild to moderate cases of CKD. For effective pain management, it is vital to evaluate the tolerability and efficacy of the available analgesics critically.http://www.jfmpc.com/article.asp?issn=2249-4863;year=2021;volume=10;issue=7;spage=2450;epage=2456;aulast=Shethdiclofenacnsaidchronic kidney diseasepain managementpain |
| spellingShingle | Sharad Sheth Sneha Thakur Anup Thorat Pankaj Gupta Safe and appropriate use of diclofenac in chronic kidney disease: An Indian perspective Journal of Family Medicine and Primary Care diclofenac nsaid chronic kidney disease pain management pain |
| title | Safe and appropriate use of diclofenac in chronic kidney disease: An Indian perspective |
| title_full | Safe and appropriate use of diclofenac in chronic kidney disease: An Indian perspective |
| title_fullStr | Safe and appropriate use of diclofenac in chronic kidney disease: An Indian perspective |
| title_full_unstemmed | Safe and appropriate use of diclofenac in chronic kidney disease: An Indian perspective |
| title_short | Safe and appropriate use of diclofenac in chronic kidney disease: An Indian perspective |
| title_sort | safe and appropriate use of diclofenac in chronic kidney disease an indian perspective |
| topic | diclofenac nsaid chronic kidney disease pain management pain |
| url | http://www.jfmpc.com/article.asp?issn=2249-4863;year=2021;volume=10;issue=7;spage=2450;epage=2456;aulast=Sheth |
| work_keys_str_mv | AT sharadsheth safeandappropriateuseofdiclofenacinchronickidneydiseaseanindianperspective AT snehathakur safeandappropriateuseofdiclofenacinchronickidneydiseaseanindianperspective AT anupthorat safeandappropriateuseofdiclofenacinchronickidneydiseaseanindianperspective AT pankajgupta safeandappropriateuseofdiclofenacinchronickidneydiseaseanindianperspective |